Should Biogen's Spinraza for SMA be delayed amid COVID-19? No, say these parents

Biogen acknowledged last week that some patients with spinal muscular atrophy are seeing their Spinraza doses delayed, as hospitals prioritize the treatment of COVID-19 patients. That's not sitting well with some parents of SMA patients, who say the drug is vital for staving off the devastating muscle loss that the disease causes.